NDATOPICALSPRAY
Approved
Apr 2013
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
TOPICORT (desoximetasone) by PharmaIN is corticosteroid hormone receptor agonists [moa]. Approved for plaque psoriasis in patients 18 years of age, older (), older and 1 more indications. First approved in 2013.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOPICORT (desoximetasone) is a potent topical corticosteroid spray approved for plaque psoriasis in adults 18 years and older. It works by binding to corticosteroid hormone receptors to suppress immune-mediated inflammation and reduce psoriatic lesions. The spray formulation offers convenient, targeted delivery to affected skin areas.
LOE Approaching2.3 years to LOE
Product approaching loss of exclusivity in 2.4 years with limited commercial runway; team size likely stable to declining as resources shift to pipeline.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (4)
Worked on TOPICORT at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.